Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Novartis Pharmaceuticals
Iain B McInnes; Frank Behrens; Philip J Mease; Arthur Kavanaugh; Christopher Ritchlin; Peter Nash; Jordi Gratacós Masmitja; Philippe Goupille; Tatiana Korotaeva; Alice B Gottlieb; Ruvie Martin; Kevin Ding; Pascale Pellet; Shephard Mpofu; Luminita Pricop; EXCEED Study Group